[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 19, 1994

Silicone Implants and Esophageal DysmotilityAre Breast-fed Infants at Risk?

Author Affiliations

From the Department of Pediatrics, Temple University School of Medicine, and Section of Gastroenterology and Nutrition, St Christopher's Hospital for Children, Philadelphia, Pa.

JAMA. 1994;271(3):240-241. doi:10.1001/jama.1994.03510270086046

The association between silicone breast implants and the development of rheumatic disease in their recipients has been suggested by a growing number of case reports.1,2 Although prospective studies of implant recipients are awaited to confirm and quantify the risk of autoimmune disease associated with silicone breast prostheses, available evidence was considered sufficient to prompt the Food and Drug Administration's January 1992 request for a voluntary moratorium on further implantation of these devices and subsequent policy restricting implant availability to controlled, clinical trials. A variety of rheumatologic diseases have been reported among implant recipients, with a high proportion of patients displaying a sclerodermalike illness. Pathogenetic mechanisms are unknown. Bleeding of silicone out of implants into periprosthetic tissues, as well as migration to more distant sites including regional lymphoid tissue, is known to occur. The potential for initiating a systemic immune response therefore exists, although most women with silicone breast implants

First Page Preview View Large
First page PDF preview
First page PDF preview